Document is current
Any future updates will be listed below
-
Authors
Shroff, Rachna T. https://orcid.org/0000-0003-0066-2672
Chalasani, Pavani
Wei, Ran
Pennington, Daniel
Quirk, Grace
Schoenle, Marta V.
Peyton, Kameron L.
Uhrlaub, Jennifer L.
Ripperger, Tyler J.
Jergović, Mladen
Dalgai, Shelby
Wolf, Alexander
Whitmer, Rebecca
Hammad, Hytham
Carrier, Amy
Scott, Aaron J.
Nikolich-Žugich, Janko
Worobey, Michael
Sprissler, Ryan
Dake, Michael https://orcid.org/0000-0002-2817-0875
LaFleur, Bonnie J. https://orcid.org/0000-0002-4939-9337
Bhattacharya, Deepta https://orcid.org/0000-0001-8377-7699
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01AI129945, R01AI099108, T32AG058503, R37AG020719)
- License Information
-
More Information
Article History
Received: 13 May 2021
Accepted: 16 September 2021
First Online: 30 September 2021
Competing interests
: Sana Biotechnology has licensed intellectual property of D.B. and Washington University in St. Louis. D.B. is a co-founder of Clade Therapeutics. B.J.L. has a financial interest in Cofactor Genomics and Iron Horse Dx. P.C. receives research funding from Pfizer, BioAtla, Zentalis, Genentech, Eli Lilly, Phoenix Molecular Designs, Amgen, Radius Pharmaceuticals, Carrick Therapeutics and Angiochem and served on advisory boards for Novartis, Eli Lilly, Zentalis, AstraZeneca, Amgen, Bayer, Asthenex, Prosigna, Heron, Puma Biotechnology and Oncosec. R.T.S. receives research funding from Merck, Rafael Pharmaceuticals, ImmunoVaccine, Bayer, SeaGen, Exelixis, Pieris, LOXO Oncology, Novocure, NuCana and QED and has served as a consultant/advisor to Merck, Servier, AstraZeneca, EMD Serono, Taiho, QED, Incyte, Genentech and Basilea. The remaining authors declare no competing interests, and no authors are employees of relevant companies.
Free to read: This content has been made available to all.
